Saturday, 31 October 2026European Markets

BSA CRE Stock Surges 20% In Five Sessions: Should Now Be The Time To Buy?

Loading stream...

(vianews) - pierre vac bsa cre (cac 40: vacbt.pa) experienced an incredible recovery over the last five sessions, increasing by 20% from eur0.35 to eur0.36 at 16:26 est on tuesday - this following five consecutive days of losses and two sessions of gains by this stock. pierre vac bsa cre closed its 52-week high price at eur0.35 but posted significant growth above this mark over this timeframe, ultimately reaching eur0.36 as its final closing price on tuesday at 16:26 est; its last closing price stood 2.27% above its 52-week high of eur0.35.

yearly analysis

based on available information, pierre vac bsa cre's stock is currently trading at eur0.36, exceeding its 52-week high of eur0.35 by 1 cent. this indicates that its performance over the past year has been positive and that a new high has been reached. investors need to conduct further analysis before making any definitive investment decisions, taking into account other factors like company financial performance, industry trends and market conditions before making their final investment decision. importantly, past results do not guarantee future returns and investing in the stock market always involves some level of risk. before making any investment decisions, investors should conduct thorough research and seek professional advice before taking action.

more news about pierre vac bsa cre (vacbt.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com